RU2016151688A3 - - Google Patents

Info

Publication number: RU2016151688A3
Authority: RU; Russia

Application number

RU2016151688A

Other versions

RU2016151688A (ru

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2011-02-18

Filing date

2012-02-18

Publication date

2020-03-06

2012-02-18 Application filed filed Critical

2018-11-15 Publication of RU2016151688A publication Critical patent/RU2016151688A/ru

2020-03-06 Publication of RU2016151688A3 publication Critical patent/RU2016151688A3/ru

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/452—Piperidinium derivatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
- A61P23/02—Local anaesthetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
- C07D207/09—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/10—Spiro-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Pain & Pain Management (AREA)
Anesthesiology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Dermatology (AREA)
Rheumatology (AREA)
Urology & Nephrology (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Hydrogenated Pyridines (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Plural Heterocyclic Compounds (AREA)
Pyrrole Compounds (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

RU2016151688A 2011-02-18 2012-02-18 Аминоиндановые соединения и их применение при лечении боли RU2016151688A (ru)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201161444379P	2011-02-18	2011-02-18
US61/444,379		2011-02-18

Related Parent Applications (1)

Application Number	Title	Priority Date	Filing Date
RU2013142433A Division RU2612959C2 (ru)	2011-02-18	2012-02-18	Аминоиндановые соединения и их применение при лечении боли

Publications (2)

Publication Number	Publication Date
RU2016151688A RU2016151688A (ru)	2018-11-15
RU2016151688A3 true RU2016151688A3 (ru)	2020-03-06

Family

ID=45787355

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
RU2013142433A RU2612959C2 (ru)	2011-02-18	2012-02-18	Аминоиндановые соединения и их применение при лечении боли
RU2016151688A RU2016151688A (ru)	2011-02-18	2012-02-18	Аминоиндановые соединения и их применение при лечении боли

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
RU2013142433A RU2612959C2 (ru)	2011-02-18	2012-02-18	Аминоиндановые соединения и их применение при лечении боли

Country Status (15)

Country	Link
US (1)	US8865741B2 (ru)
EP (3)	EP2675787B1 (ru)
JP (1)	JP6184328B2 (ru)
KR (4)	KR101938684B1 (ru)
CN (2)	CN103547566B (ru)
AU (5)	AU2012219254B2 (ru)
BR (1)	BR112013020874A2 (ru)
CA (1)	CA2826648C (ru)
DK (2)	DK3363437T3 (ru)
ES (2)	ES2675510T3 (ru)
IL (1)	IL227967A (ru)
MX (2)	MX386293B (ru)
RU (2)	RU2612959C2 (ru)
UA (1)	UA112769C2 (ru)
WO (1)	WO2012112969A1 (ru)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8809372B2 (en)	2011-09-30	2014-08-19	Asana Biosciences, Llc	Pyridine derivatives
EP2771320B1 (en)	2011-10-24	2016-06-22	Endo Pharmaceuticals Inc.	Cyclohexylamines
US9044482B2 (en) *	2012-08-15	2015-06-02	Asana Biosciences, Llc	Use of aminoindane compounds in treating overactive bladder and interstitial cystitis
EP2956440B1 (en)	2013-02-08	2018-04-11	General Mills, Inc.	Reduced sodium food products
TWI799366B (zh) *	2015-09-15	2023-04-21	美商建南德克公司	胱胺酸結骨架平臺
CN106214678B (zh) *	2016-07-26	2020-12-29	上海璃道医药科技有限公司	苯酮类药物的用途
CN113329744A (zh) *	2018-11-30	2021-08-31	阿沙纳生物科学公司	用于改良活性药物成分的稳定性的制剂、方法、试剂盒和剂型
WO2025245656A1 (en)	2024-05-27	2025-12-04	Libertas Bio, Inc.	Crystalline solid forms of sodium channel blockers

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
BE760018A (fr)	1969-12-19	1971-06-08	Christiaens Sa A	Nouveau derives du 2-amino-indane, leur preparation et leur utilisation
ZA738419B (en) *	1972-11-06	1974-09-25	Christiaens Sa A	New derivatives of 2-aminoindane,the preparation and use thereof
US5411738A (en)	1989-03-17	1995-05-02	Hind Health Care, Inc.	Method for treating nerve injury pain associated with shingles (herpes-zoster and post-herpetic neuralgia) by topical application of lidocaine
US5190956A (en)	1990-09-07	1993-03-02	Schering Corporation	Certain N-substituted 3-oximino-2,4-dioxoquinolin-2,4-(1H)diones useful for treating viral infections
US5344836A (en)	1991-11-11	1994-09-06	Ono Pharmaceutical Co., Ltd.	Fused benzeneoxyacetic acid derivatives
US5854268A (en)	1994-08-02	1998-12-29	Merck Sharp & Dohme, Ltd.	Azetidine, pyrrolidine and piperidine derivatives
JP3471122B2 (ja)	1995-04-26	2003-11-25	アルケア株式会社	医療用粘着配合物
GB9523243D0 (en)	1995-11-14	1996-01-17	Merck Sharp & Dohme	Therapeutic agents
SE508357C2 (sv)	1996-01-02	1998-09-28	Kay Laserow	Mätinstrument för mätning av smärta jämte ett förfarande för att med ett mätinstrument mäta smärta
GB9610979D0 (en)	1996-05-24	1996-07-31	Merck Sharp & Dohme	Therapeutic agents
WO1998024428A1 (en) *	1996-12-02	1998-06-11	Brigham & Women's Hospital, Inc.	Long-acting local anesthetics
SE9604751D0 (sv)	1996-12-20	1996-12-20	Astra Ab	New therapy
US6623040B1 (en)	1997-09-03	2003-09-23	Recot, Inc.	Method for determining forced choice consumer preferences by hedonic testing
CN1814589A (zh) *	1999-06-10	2006-08-09	布里奇药品有限公司	皮肤麻醉剂
AU777517B2 (en)	1999-06-10	2004-10-21	Bridge Pharma, Inc.	Dermal anesthetic agents
WO2001000656A2 (en)	1999-06-29	2001-01-04	Ortho-Mcneil Pharmaceutical, Inc.	Novel indazole peptidomimetics as thrombin receptor antagonists
US6630451B1 (en)	1999-06-29	2003-10-07	Orthomcneil Pharmaceutical, Inc.	Benzimidazolone peptidometics as thrombin receptor antagonist
US6858577B1 (en)	1999-06-29	2005-02-22	Ortho-Mcneil Pharmaceutical, Inc.	Indole peptidomimetics as thrombin receptor antagonists
WO2001005767A1 (en)	1999-07-20	2001-01-25	Novartis Ag	Organic compounds
AU1309701A (en)	1999-11-15	2001-05-30	Nissan Chemical Industries Ltd.	Hydrazone compounds and pesticides
SK4322003A3 (en)	2000-10-12	2003-09-11	Merck & Co Inc	Aza- and polyaza-naphthalenyl carboxamides useful as HIV integrase inhibitors
ES2324461T3 (es)	2000-10-13	2009-08-07	Alza Corporation	Aparato y procedimiento para perforar la piel con microprotuberancias.
CZ20031164A3 (cs)	2000-10-26	2004-04-14	Alza Corporation	Zařízení s potaženými mikrovýčnělky pro transdermální přenos léku
US6766319B1 (en)	2000-10-31	2004-07-20	Robert J. Might	Method and apparatus for gathering and evaluating information
US20020147198A1 (en)	2001-01-12	2002-10-10	Guoqing Chen	Substituted arylamine derivatives and methods of use
US7105682B2 (en)	2001-01-12	2006-09-12	Amgen Inc.	Substituted amine derivatives and methods of use
US7102009B2 (en)	2001-01-12	2006-09-05	Amgen Inc.	Substituted amine derivatives and methods of use
US6995162B2 (en)	2001-01-12	2006-02-07	Amgen Inc.	Substituted alkylamine derivatives and methods of use
US20030134836A1 (en)	2001-01-12	2003-07-17	Amgen Inc.	Substituted arylamine derivatives and methods of use
DE60225709T2 (de)	2001-11-01	2009-05-07	Janssen Pharmaceutica N.V.	Aminobenzamidderivate als inhibitoren der glycogensynthasekinase-3-
SI1321139T1 (sl)	2001-12-21	2007-02-28	Chiesi Farma Spa	2-indanilamino-derivati za zdravljenje kronicne, akutne ali vnetne bolecine
JP4216196B2 (ja)	2002-02-04	2009-01-28	エフ．ホフマン−ラロシュアーゲー	Ｎｐｙアンタゴニストとしてのキノリン誘導体
MXPA05006123A (es)	2002-12-13	2005-09-30	Neurogen Corp	Analogos de quinazolin-4-ilamina 2-sustituida como moduladores de receptores de capsaicina.
EP1613597B1 (en)	2003-03-07	2007-11-07	Eli Lilly and Company	6-substituted nicotinamide derivatives as opioid receptor antagonists
WO2006036936A2 (en) *	2004-09-27	2006-04-06	Bridge Pharma, Inc.	The s-isomer of 2-{2-[n-(2-indanyl)-n-phenylamino]ethyl}piperidine and other dermal anesthetic agents
US20060079558A1 (en)	2004-09-27	2006-04-13	Bridge Pharma. Inc.	R-isomer of 2-{2[N-(2-indanyl)-N-phenylamino]ethyl}piperidine and other dermal anesthetics
EP1659113A1 (en)	2004-11-08	2006-05-24	Evotec AG	Inhibitors of 11beta-hydroxy steroid dehydrogenase type 1 (11beta-HSD1)
EP1655283A1 (en)	2004-11-08	2006-05-10	Evotec OAI AG	11beta-HSD1 Inhibitors
CA2587780A1 (en)	2004-11-18	2006-05-26	Transpharma Medical Ltd.	Combined micro-channel generation and iontophoresis for transdermal delivery of pharmaceutical agents
US20090137628A1 (en) *	2005-09-23	2009-05-28	Bridge Pharma, Inc.	Formulations of Indanylamines and the Use Thereof as Local Anesthetics and as Medication for Chronic Pain
CN101365684A (zh) *	2005-10-28	2009-02-11	艾博特公司	抑制trpv1受体的吲唑衍生物
GB0525029D0 (en)	2005-12-08	2006-01-18	Univ Hull	Receptor Antagonist
TWI409256B (zh)	2006-09-01	2013-09-21	Dow Agrosciences Llc	殺蟲性之ｎ-取代（雜芳基）環烷基磺醯亞胺
TWI383970B (zh)	2006-11-08	2013-02-01	Dow Agrosciences Llc	多取代的吡啶基磺醯亞胺及其作為殺蟲劑之用途
JP2010510227A (ja)	2006-11-20	2010-04-02	プレジデントアンドフェロウズオブハーバードカレッジ	痛みおよび痒みの治療方法、組成物およびキット
EP2114885B1 (en)	2007-02-09	2016-01-27	Dow AgroSciences LLC	Process for the oxidation of certain substituted sulfilimines to insecticidal sulfoximines
US7511149B2 (en)	2007-02-09	2009-03-31	Dow Agrosciences Llc	Process for the oxidation of certain substituted sulfilimines to insecticidal sulfoximines
WO2008099022A1 (en)	2007-02-16	2008-08-21	Tibotec Pharmaceuticals Ltd.	10-sulfonyl-dibenzodiazepinones useful as hepatitis c virus inhibitors
EP2225223B1 (de)	2007-11-22	2017-01-11	Boehringer Ingelheim International GmbH	Organische verbindungen
WO2009065921A2 (de)	2007-11-22	2009-05-28	Boehringer Ingelheim International Gmbh	Organischeverbindungen
EP2062889A1 (de)	2007-11-22	2009-05-27	Boehringer Ingelheim Pharma GmbH & Co. KG	Verbindungen
US20120149698A1 (en)	2007-11-22	2012-06-14	Boehringer Ingelheim International Gmbh	Nouvel compounds
BRPI0909627A2 (pt)	2008-03-11	2018-04-10	Harvard College	métodos, composições e kits para tratar dores e pruridos
AU2009283085A1 (en)	2008-08-20	2010-02-25	Merck Sharp & Dohme Corp.	Non-amidic linkers with branched termini as CGRP receptor antagonists
EP2451944A4 (en)	2009-07-10	2012-11-28	Harvard College	PERMANENTLY CHARGED SODIUM AND CALCIUM CHANNEL BLOCKERS AS ANTI-INFLAMMATORY AGENTS

2012
- 2012-02-18 UA UAA201311103A patent/UA112769C2/uk unknown
- 2012-02-18 MX MX2017008878A patent/MX386293B/es unknown
- 2012-02-18 JP JP2013554666A patent/JP6184328B2/ja active Active
- 2012-02-18 AU AU2012219254A patent/AU2012219254B2/en active Active
- 2012-02-18 KR KR1020137023468A patent/KR101938684B1/ko active Active
- 2012-02-18 ES ES12706985.4T patent/ES2675510T3/es active Active
- 2012-02-18 DK DK18157055.7T patent/DK3363437T3/da active
- 2012-02-18 RU RU2013142433A patent/RU2612959C2/ru not_active IP Right Cessation
- 2012-02-18 EP EP12706985.4A patent/EP2675787B1/en active Active
- 2012-02-18 WO PCT/US2012/025759 patent/WO2012112969A1/en not_active Ceased
- 2012-02-18 EP EP18157055.7A patent/EP3363437B8/en active Active
- 2012-02-18 KR KR1020187018400A patent/KR102014203B1/ko active Active
- 2012-02-18 CN CN201280016004.8A patent/CN103547566B/zh active Active
- 2012-02-18 RU RU2016151688A patent/RU2016151688A/ru not_active Application Discontinuation
- 2012-02-18 ES ES18157055T patent/ES2898910T3/es active Active
- 2012-02-18 CA CA2826648A patent/CA2826648C/en active Active
- 2012-02-18 KR KR1020197024272A patent/KR102173572B1/ko active Active
- 2012-02-18 EP EP21187447.4A patent/EP3970723A1/en active Pending
- 2012-02-18 KR KR1020207031145A patent/KR20200125765A/ko not_active Ceased
- 2012-02-18 CN CN201710350820.7A patent/CN107540599B/zh active Active
- 2012-02-18 MX MX2013009537A patent/MX348961B/es active IP Right Grant
- 2012-02-18 DK DK12706985.4T patent/DK2675787T3/en active
- 2012-02-18 US US13/400,039 patent/US8865741B2/en active Active
- 2012-02-18 BR BR112013020874-0A patent/BR112013020874A2/pt not_active Application Discontinuation
2013
- 2013-08-15 IL IL227967A patent/IL227967A/en active IP Right Grant
2016
- 2016-11-11 AU AU2016256819A patent/AU2016256819C1/en not_active Ceased
2018
- 2018-11-09 AU AU2018260936A patent/AU2018260936B2/en active Active
2020
- 2020-11-26 AU AU2020277232A patent/AU2020277232C1/en active Active
2023
- 2023-04-06 AU AU2023202157A patent/AU2023202157B2/en active Active

Also Published As

Publication number	Publication date
CA2826648A1 (en)	2012-08-23
CN103547566A (zh)	2014-01-29
AU2018260936B2 (en)	2020-08-27
ES2675510T3 (es)	2018-07-11
KR102173572B1 (ko)	2020-11-03
KR20200125765A (ko)	2020-11-04
JP2014505739A (ja)	2014-03-06
US8865741B2 (en)	2014-10-21
MX386293B (es)	2025-03-18
EP3970723A1 (en)	2022-03-23
KR101938684B1 (ko)	2019-01-16
ES2898910T3 (es)	2022-03-09
KR20180079459A (ko)	2018-07-10
AU2016256819A1 (en)	2016-12-01
DK2675787T3 (en)	2018-07-16
EP2675787A1 (en)	2013-12-25
KR20140021553A (ko)	2014-02-20
AU2023202157B2 (en)	2024-10-31
KR20190101481A (ko)	2019-08-30
DK3363437T3 (da)	2021-11-01
EP3363437B8 (en)	2021-11-03
RU2016151688A (ru)	2018-11-15
EP2675787B1 (en)	2018-03-28
UA112769C2 (uk)	2016-10-25
BR112013020874A2 (pt)	2019-05-21
HK1248704A1 (zh)	2018-10-19
RU2612959C2 (ru)	2017-03-14
IL227967A0 (en)	2013-09-30
AU2023202157A1 (en)	2023-05-04
CN107540599A (zh)	2018-01-05
AU2020277232A1 (en)	2020-12-24
CN107540599B (zh)	2021-06-04
AU2012219254A1 (en)	2013-08-29
AU2016256819C1 (en)	2019-02-21
AU2012219254B2 (en)	2016-08-11
AU2018260936A1 (en)	2018-11-29
AU2016256819B2 (en)	2018-08-09
EP3363437B1 (en)	2021-07-28
MX348961B (es)	2017-07-04
IL227967A (en)	2017-04-30
US20120214809A1 (en)	2012-08-23
RU2013142433A (ru)	2015-03-27
CN103547566B (zh)	2017-05-31
CA2826648C (en)	2019-06-04
MX2013009537A (es)	2014-01-08
EP3363437A1 (en)	2018-08-22
AU2020277232B2 (en)	2023-01-12
WO2012112969A1 (en)	2012-08-23
AU2020277232C1 (en)	2023-08-03
KR102014203B1 (ko)	2019-08-26
JP6184328B2 (ja)	2017-08-23

Publication	Publication Date	Title
BR112013022641A2 (ru)	2017-09-21
BR112013031251A2 (ru)	2017-09-12
BR112013027245A2 (ru)	2017-01-03
BR112013024383A2 (ru)	2021-12-07
BR112013026905A2 (ru)	2017-01-03
BR112013022995A2 (ru)	2012-09-13
BR112013017670A2 (ru)	2017-08-15
BR112013027830A2 (ru)	2017-01-03
BR112013026744A2 (ru)	2017-01-03
BR112013027452A2 (ru)	2017-01-03
BR112013024365A2 (ru)	2017-01-03
BR112013028733A2 (ru)	2017-08-29
BR112013027121A2 (ru)	2017-01-03
BR112013024588A2 (ru)	2017-01-03
BR112013031556A2 (ru)	2017-08-29
BR112013026790A2 (ru)	2017-05-02
BR112013032368A2 (ru)	2017-01-03
BR112013032380A2 (ru)	2017-01-03
BR112013032377A2 (ru)	2017-01-03
BR112013027836A2 (ru)	2017-01-03
BR112013018949A2 (ru)	2017-09-12
BR112013026895A2 (ru)	2017-01-03
BR112013027761A2 (ru)	2017-01-03
BR112013021637A2 (ru)	2012-11-01
BR112013032392A2 (ru)	2017-01-03

Legal Events

Date	Code	Title	Description
2020-09-10	FA92	Acknowledgement of application withdrawn (lack of supplementary materials submitted)	Effective date: 20200908